KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Revenue (2016 - 2025)

Biogen (BIIB) has 17 years of Revenue data on record, last reported at $2.3 billion in Q4 2025.

  • For Q4 2025, Revenue fell 7.14% year-over-year to $2.3 billion; the TTM value through Dec 2025 reached $9.9 billion, up 2.22%, while the annual FY2025 figure was $9.9 billion, 2.22% up from the prior year.
  • Revenue reached $2.3 billion in Q4 2025 per BIIB's latest filing, down from $2.5 billion in the prior quarter.
  • Across five years, Revenue topped out at $2.8 billion in Q3 2021 and bottomed at $2.3 billion in Q4 2025.
  • Average Revenue over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2022.
  • Peak YoY movement for Revenue: dropped 24.63% in 2021, then grew 7.33% in 2025.
  • A 5-year view of Revenue shows it stood at $2.7 billion in 2021, then dropped by 6.94% to $2.5 billion in 2022, then dropped by 0.54% to $2.5 billion in 2023, then fell by 2.99% to $2.5 billion in 2024, then decreased by 7.14% to $2.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $2.3 billion in Q4 2025, $2.5 billion in Q3 2025, and $2.6 billion in Q2 2025.